News
OGEN
--
0.00%
--
Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
Business Wire · 11/24 16:37
Mid-Afternoon Market Update: Dow Drops Over 100 Points; Mesoblast Shares Spike Higher
Toward the end of trading Friday, the Dow traded down 0.46% to 29,346.95 while the NASDAQ rose 0.14% to 11,920.95. The S&P also fell, dropping 0.20% to 3,574.82.
Benzinga · 11/20 19:32
Mid-Day Market Update: Nasdaq Edges Higher; Nano Dimension Shares Plunge
Midway through trading Friday, the Dow traded down 0.43% to 29,355.69 while the NASDAQ rose 0.14% to 11,921.21. The S&P also fell, dropping 0.24% to 3,573.32.
Benzinga · 11/20 17:37
Oragenics shares drop 28% after pricing $5.25M stock offering
Oragenics (OGEN) plunges 28% premarket after pricing its public offering of ~14.2M common shares at $0.37/share, for expected gross proceeds of ~$5.25M.Underwriters' over-allotment is an additional 2,128,378 shares. Net proceeds will be used
Seekingalpha · 11/20 13:42
Oragenics Prices $5.25M Offering Of 14.189M Shares At $0.37/Share
Oragenics Prices $5.25 Million Common Stock Offering Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a company focused on the creation of the Terra CoV-2 vaccine candidate to combat
Benzinga · 11/20 13:32
Oragenics Prices $5.25 Million Common Stock Offering
ORAGENICS PRICES $5.25 MILLION COMMON STOCK OFFERING
Business Wire · 11/20 13:30
CORRECTING AND REPLACING Oragenics Announces Proposed Underwritten Public Offering
Oragenics Announces Proposed Underwritten Public Offering
Business Wire · 11/19 22:14
Oragenics launches equity offering
Oragenics (OGEN) down 1% AH, has commenced a proposed underwritten public offering of common stock.Volume, price are yet to be determined.
Seekingalpha · 11/19 21:27
Why Oragenics Stock Is Trading Higher Today
Oragenics (NYSE: OGEN) shares are trading higher on Tuesday after the company announced the FDA broadly supports its pre-IND development program for its SARS-CoV-2 vaccine.
Benzinga · 10/06 14:35
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 6, 2020: DPZ, AZYO, OGEN, ALKS, AN
Today's 5 Stock Ideas:  Domino’s Pizza (DPZ) - Will report Q3 earnings before market open on Thursday. Analysts expect EPS of $2.71 on revenue of $943.77 million.  Aziyo Biologics
Benzinga · 10/06 12:10
FDA backs Oragenics' Pre-IND development program for SARS-CoV-2 vaccine
Oragenics (OGEN) jumps 19% premarket after receiving feedback to Type B Pre-IND Meeting Request from the FDA that the Agency is in broad agreement with the Company’s clinical development program for its SARS-CoV-2
Seekingalpha · 10/06 11:41
FDA Broadly Supports Oragenics' Pre-IND Development Program for its SARS-CoV-2 Vaccine; Re-Affirms Plan to File IND Application by the End of 1Q21, Begin Phase 1 Study in Early 2Q21
TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE:OGEN) (“Oragenics” or the “Company”) announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug
Benzinga · 10/06 11:31
Oragenics comes up empty in pursuit BARDA funding for COVID-19 vaccine
Nano cap Oragenics (OGEN) reports that the U.S. Health and Human Services' Biomedical Advanced Research and Development Authority ((BARDA)) has decided to pass on funding the development of COVID-19 vaccine
Seekingalpha · 09/28 11:48
Oragenics Says Has Been Informed Of BARDA's Determination Not To Enter Negotiation With Co.; Says 'a combination of factors, including availability of funds, precluded the agency from entering into negotiations at this time.'
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") provides an update on U.S. federal government and other funding options the Company is pursuing in order to advance its SARS-CoV-2
Benzinga · 09/28 11:32
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
Business Wire · 09/11 11:30
OGEN: SARS-CoV-2 Vaccine to Enter the Clinic in Early 2021
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Developing Vaccine Against SARS-CoV-2 In May 2020, Oragenics, Inc. (NYSE:OGEN) announced the acquisition of Noachis Terra Inc., which is developing TerraCoV2, a vaccine candidate against SARS-CoV-2 (the virus that causes
Zacks Small Cap Research · 09/03 14:47
Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine
Business Wire · 08/20 13:30
Oragenics inks deal with Avid Bio for advancement of COVID-19 vaccine
Oragenics (OGEN) soars 24% premarket after entering into a process development and drug substance manufacturing agreement with Avid Bioservices (CDMO), up 5%.Under terms of the agreement, Avid will provide Oragenics with analytical method
Seekingalpha · 08/20 12:59
Ocugen and vTv Therapeutics among healthcare gainers; Vaxart leads the losers
Seeking Alpha · 07/27 15:02
INTC, NIO among premarket losers
Seeking Alpha - Article · 07/24 12:24
Webull provides a variety of real-time OGEN stock news. You can receive the latest news about ORAGENICS through multiple platforms. This information may help you make smarter investment decisions.
About OGEN
Oragenics, Inc. is a healthcare company. The Company is focused on developing treatments for oral mucositis and novel antibiotics against infectious disease. The Company is focused on developing of the TerraCoV2 immunization product candidate. The Company’s product candidate includes, OG716, as an antibiotic, as well as other homolog antibiotic product candidates and AG013 for the treatment of oral mucositis in patients undergoing treatment for cancer. The Company have developed other product such as weight loss candidate, LPT3-04 and SMaRT Replacement Therapy.
More